Drug Approval | May 01, 2026
Dr Reddy’s becomes first to secure Health Canada nod for generic Semaglutide injection
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Pharma and biotech infrastructure firm targets 25–30% growth as Middle East and Africa emerge as key expansion markets
The trials -- ELOWEN-1 and ELOWEN-2 -- are designed to evaluate the drug in people living with lupus who experience active skin manifestations
With the convergence of AI, robotics, and neuroscience, Motorica is advancing toward more intuitive, intent-driven prosthetic systems
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
The twin designations are designed to speed up the development and review of promising medicines targeting serious conditions with high unmet need
The agreement could rise to $900 million if key commercial milestones are met
Health innovations are viewed more positively than food and agricultural technologies
Union health minister urges graduates in Chandigarh to combine technological excellence with compassion in medical practice
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Subscribe To Our Newsletter & Stay Updated
